Amylin Pharmaceuticals Inc., of San Diego, promoted Daniel Bradbury to president and chief operating officer, and to its board.

Archemix Corp., of Cambridge, Mass., appointed John Maraganore to its board.

Aspreva Pharmaceuticals Corp., of Victoria, British Columbia, appointed William Hunter to its board.

AtheroGenics Inc., of Atlanta, appointed Brian Blakey vice president of marketing.

BioSyntech Inc., of Laval, Quebec, appointed Rudy Huber and Joyce Tsang to its board.

Cardiome Pharma Corp., of Vancouver, British Columbia, appointed Curtis Sikorsky chief financial officer.

Cardium Therapeutics Inc., of San Diego, appointed Gabor Rubanyi chief scientific officer.

Carrington Laboratories Inc., of Irving, Texas, promoted Yawei Ni to senior scientist at DelSite Biotechnologies Inc., its wholly owned subsidiary.

Catalyst Biosciences Inc., of South San Francisco, appointed Marc Navre vice president of drug discovery.

Celldex Therapeutics Inc., of Phillipsburg, N.J., appointed Thomas Davis chief medical officer and vice president of clinical development, and Tibor Keler chief scientific officer and vice president of research and development.

Ceres Inc., of Thousand Oaks, Calif., appointed Patrick McCroskey chief financial officer.

Cerimon Pharmaceuticals Inc., of South San Francisco, appointed James Welch chief financial officer.

Chromos Molecular Systems Inc., of Burnaby, British Columbia, appointed Jeff Charpentier vice president, finance and chief financial officer.

Clinical Cell Culture Ltd., of Sydney, Australia, appointed Bob Atwill CEO and a director. Andrew Cannon also joined the board.

Corgentech Inc., of South San Francisco, appointed Peony Yu vice president of clinical research, Michael Leong director of clinical research and Susan Kramer vice president of preclinical development.

Cougar Biotechnology Inc., of Los Angeles, appointed Michael Richman to its board.

Crucell NV, of Leiden, the Netherlands, appointed Jan Oosterveld chairman.

CytoDyn Inc., of Santa Fe, N.M., appointed Jonathan Leong to its board.

No Comments